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Introduction: Anti-acetylcholine receptor (AChR) autoantibodies target muscles in spontaneous human myasthenia
gravis (MG) and its induced experimental autoimmune model MG (EAMG). The aim of this study was to identify
novel functional mechanisms occurring in the muscle pathology of myasthenia.
Results: A transcriptome analysis performed on muscle tissue from MG patients (compared with healthy controls) and
from EAMG rats (compared with control rats) revealed a deregulation of genes associated with the Interleukin-6 (IL-6)
and Insulin-Like Growth Factor 1 (IGF-1) pathways in both humans and rats. The expression of IL-6 and its receptor
IL-6R transcripts was found to be altered in muscles of EAMG rats and mice compared with control animals. In muscle
biopsies from MG patients, IL-6 protein level was higher than in control muscles. Using cultures of human muscle cells,
we evaluated the effects of anti-AChR antibodies on IL-6 production and on the phosphorylation of Protein Kinase B
(PKB/Akt). Most MG sera and some monoclonal anti-AChR antibodies induced a significant increase in IL-6 production
by human muscle cells. Furthermore, Akt phosphorylation in response to insulin was decreased in the presence of
monoclonal anti-AChR antibodies.
Conclusions: Anti-AChR antibodies alter IL-6 production by muscle cells, suggesting a putative novel functional
mechanism of action for the anti-AChR antibodies. IL-6 is a myokine with known effects on signaling pathways
such as Akt/mTOR (mammalian Target of Rapamycin). Since Akt plays a key role in multiple cellular processes, the
reduced phosphorylation of Akt by the anti-AChR antibodies may have a significant impact on the muscle fatigability
observed in MG patients.
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Myasthenia gravis (MG) is an organ-specific T cell-mediated
autoimmune disease in which autoantibodies against nico-
tinic acetylcholine receptors (AChR) at the postsynaptic
membrane are responsible for a loss of functional AChR and
impaired neuromuscular transmission. The immunopatho-
genic mechanisms that cause a loss of functional AChR
include antigenic modulation by anti-AChR antibodies,
complement-mediated focal lysis of the postsynaptic mem-
brane, and direct interference with binding of acetylcholine* Correspondence: sonia.berrih-aknin@upmc.fr
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unless otherwise stated.to AChR [1,2]. Experimental autoimmune MG (EAMG)
mimics human MG in its clinical and immunopathological
manifestations. EAMG induced in rats is the most reliable
model for delineating the immunopathological factors and
processes involved in MG and for investigating therapeutic
strategies for MG [3,4], including treatments aimed at redu-
cing impaired muscle function [5].
Despite the vast body of knowledge accumulated in re-
cent years regarding the underlying immunological mech-
anisms in MG and EAMG, the molecular mechanisms
involved in muscle pathology still remain unclear. Studies
of both humans and rats have shown an increased expres-
sion of AChR transcripts in the muscles of myasthenic pa-
tients or EAMG animals [6-8], suggesting a mechanism of
compensation that occurs after the autoimmune attack. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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genes and pathways has not been investigated.
Microarrays have enabled the identification of specific
biomarkers in several autoimmune diseases [10,11]. For
example, in type I diabetes, transcriptome studies in pa-
tients and Non-Obese Diabetic mouse models revealed
similar inflammatory pathways inducible by IL-1β and
interferons (IFNs) in the periphery that aided the identi-
fication of new biomarkers [10]. In MG, very few studies
have used this pan-genomic approach. Our own studies
comparing the transcriptome of human normal and
pathological thymus yielded a discovery of several novel
pathways and pathogenic mechanisms involved in the
immune deregulation. We found an inflammatory and
anti-viral signature in the thymus of MG patients, as
well as a deregulation in immunoglobulin production
[12,13]. An abnormal expression of two chemokines,
CXCL13 and CCL21, led us to extensively explore these
chemokines, revealing their role in the development of
thymic germinal centers [14]. A similar analysis in
EAMG identified the CXCR3/IP10 pathway deregulated
in the lymph nodes of the induced rat model [15]. A
specific study of this gene family showed that CXCR3
and IP10 were overexpressed in both EAMG and human
MG [15]. Finally, anti-CXCR3 molecules are able to pre-
vent the development of MG disease in the rat-induced
model [16]. This example illustrates how a molecule dis-
covered in a pan-genomic study could finally be a thera-
peutic target.
Our goal here is to identify genes and molecular path-
ways deregulated in the muscles of MG patients and
EAMG. To this end, we compared, for the first time, the
muscle transcriptome in seropositive MG (SPMG) patients
with healthy muscle, and in parallel, we performed a simi-
lar analysis in myasthenic rats. Our analyses revealed the
involvement of the IL-6 and IGF-1 signaling pathways. Cell
culture experiments demonstrated that anti-AChR anti-
bodies increased IL-6. An analysis of Akt, a common mol-
ecule downstream of these two pathways, revealed that
monoclonal anti-AChR antibodies decreased the phos-
phorylation of Akt by insulin. In conclusion, these results
show that the pathological mechanisms occurring in the
muscle of MG patients and EAMG rats are essentially
similar and induce profound cellular changes, including
deregulation of the IL-6 and IGF-1 pathways.
Materials and methods
Study subjects
Biopsies from the pectoralis of MG patients were collected
during thymectomies (Marie Lannelongue Hospital, Le
Plessis Robinson). RNA was extracted, and the quality
controlled as described below. When the RNA was not
high quality, it was excluded. Finally, three positive MG
patients with common features were included in themicroarray experiments. These patients were young
(24-, 26-, and 27-year-old) females, positive for anti-AChR
antibodies (6, 10, and 27 nM), with a generalized form dis-
ease (IIB in 2 cases, and IIIB in 1 case), and untreated by
corticosteroids. Since muscle controls from age- and sex-
matched individuals were not available at the time of the
microarray experiments, a pool of RNA from muscle
biopsies from healthy adults (reference HT1008) was
provided by Origene Technology (Rockville, MD, USA).
In order to test the IL-6 protein levels in the muscles,
another set of muscle biopsies was collected from SPMG
patients (12–49 years old; 6 females and 2 males, from
Ia–IVb) and control patients (17–51 years old; 5 females
and 2 males). The muscle biopsies from MG patients
were collected during thymectomy when the patients
were in a clinical stable status, and they were rarely very
severely affected. Only one patient had a very severe
form (IVb). The muscles from the control patients were
collected during cardiac surgery, enabling sampling of
the same muscle (pectoralis) as in the MG patients.
None of the control patients had other skeletal muscle
diseases. Thymus histologies from these MG patients
ranged from normal (1) to involuted thymus (1) and
follicular hyperplasia (4).
For the effects of sera on IL-6 production, 6 SPMG pa-
tients (6 females; age range: 18–34 years, 1 with MG se-
verity IIA, 4 with IIB, and 1 with IIIA) and 6 seronegative
MG (SNMG) patients (5 females and 1 male; age range:
19–55 years, 3 with MG severity I, 2 with IIB, and 1 with
IIIB) were included. SNMG patients were also negative for
anti-MuSK antibodies. Patients on corticosteroid treat-
ment were excluded from the study. Sera from 6
healthy controls, aged 18–45 years, were obtained from
the French blood bank. Sera from 6 patients suffering
from other muscle diseases were also used: 2 with
glycogen storage disease, type III, 1 fascio-scapulo-
humeral dystrophy, 1 desminopathy, 1 neuroectoder-
mosis, and 1 spinal amyotrophy.
Ethics and consent
All the procedures were approved by the local ethics com-
mittee “Comité de Protection des Personnes (CPP)”,
Kremlin-Bicêtre, France (agreement number 06–018). The
muscle biopsies were obtained from MG and non-MG
patients who signed an informed consent.
Animals and antigen preparation
Female Lewis rats aged 6–7 weeks were obtained from
the Animal Breeding Center of The Weizmann Institute
of Science, and were maintained in the Institute’s animal
facility. Female C57Bl/6 J mouse aged 5 weeks were ob-
tained from Janvier laboratories and acclimatized one
week in the animal facility (University Pierre and Marie
Curie) prior to immunization. All of the experiments in
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guidelines for animal care. Torpedo AChR was purified
from the electric organ of Torpedo californica by affinity
chromatography, as previously described [17].
Induction and clinical evaluation of EAMG
To induce EAMG, rats were immunized once in both
hind footpads via a subcutaneous injection of Torpedo
AChR (40 μg/rat) emulsified in complete Freund’s adju-
vant (CFA) supplemented with additional non-viable
Mycobacterium tuberculosis H37RA (0.5 mg/rat; Difco
Laboratories, Detroit, MI, USA). The control rats were
immunized with CFA and H37RA. Clinical signs of
EAMG were monitored on alternate days for 8–10 weeks
following disease induction, as previously described [15].
Six-week female mice were immunized by subcutaneous
injections in both hind footpads and in the back with
Torpedo AChR (30 μg/mouse) emulsified in CFA supple-
mented with H37RA (1 mg/mouse). Control mice were
immunized with CFA and H37RA. Approximately 30 days
later, the mice received a subcutaneous boost in the back
of the same amount of TAChR in CFA, without additional
H37RA; the control mice received a similar boost. The
mice were monitored for muscle force and weakness every
10 days. A global score based on the animals’ weights, grip
force, and ability to remain on an inverted grid was calcu-
lated to quantify their clinical state. Each of these three
parameters was graded on a scale of 0–3 to yield a final
score on 9, where 0 corresponded to healthy mice and
9 corresponded to severely affected mice.
Microarray experiments
Strategy of the microarray
We adopted a strategy previously used for MG thymus
analysis using pools of thymic tissues from homogeneous
groups of patients [13,18]. Many of the deregulated genes
identified by this approach were then validated in bio-
logical studies, such as CXCL13 [19], IFNs [12], and
CCL21 [14]. By using pools of muscle tissue instead of in-
dividual tissue, we focused our analysis on the primary
common changes instead of individual changes. This strat-
egy was validated by our biostatistian (GC). Another ad-
vantage of using pools is the ability to perform several
technical replicates (quadruplicates in the current study),
which is impossible with individual tissue given limitations
of both tissue and money. Indeed, performing technical
replicates is important to strengthen the results since
manipulation of a high number of normalized data can
lead to a significant rate of false-negative results.
GeneChip probing and analysis
Rat muscle samples
Muscle samples were harvested from rats when they
reached a clinical score of 2 [15]. Since the disease isinduced in the hind legs, the thigh muscles that are also
affected were used for the extraction of total RNA
using the RNeasy midi kit (Qiagen GmbH, Hilden,
Germany). Two RNA samples were used for each
group, and each sample consisted of a pool from three
individual rats.
The GeneChip RG-U34A arrays (Affymetrix, Santa
Clara, CA, USA) containing probes for 8000 rat genes
and 1000 ESTs were used to screen and quantify the
mRNA transcript level in rat thigh muscle samples.
Probing and analysis of these samples were performed
at the Weizmann Institute microarray unit, as previ-
ously described in the literature [15]. Genes showing a
fold change greater than 2 were selected for further
evaluation.Human muscle samples
Total RNA from muscles of MG patients or from
muscle controls (Origene Technology) was extracted
using the Trizol reagent (Gibco, Paisley, Scotland) and
purified, as previously described in the literature [18].
The sample concentration and purity was first assessed
using the NanoDrop spectrophotometer. Then the qual-
ity control to assess the sample integrity was checked on
an Agilent Bioanalyser (Massy, France). For microarray
analysis. only high quality RNAs with RIN (RNA integ-
rity number ) higher than 7, in a scale ranging from
from 1 (totally degraded RNA) to 10 (completely intact
RNA) were used. Twenty μg of total muscle RNA was
labeled with cyanine 5 or cyanine 3 using the direct label-
ing protocol of Agilent optimized for their cDNA chips, as
previously described [19]. For each array, the control
muscle RNA was crossed with RNA from MG muscle and
these comparisons were conducted in quadruplicate. All
of the procedures have been detailed elsewhere [19,13].
Briefly, the labeled cDNA was hybridized overnight onto
the human 1 cDNA arrays from Agilent (G4100A; 12,814
unique clones) and scanned using a 428 Affimetrix
scanner (MWG Biotech). The images were analyzed
with a GenePix pro V4.0 (Axon Instruments). The raw
data were then corrected by a non-linear transform-
ation (the Lowess algorithm) using a TIGR Microarray
Data Analysis System (www.tm4.org/midas.html). A
statistical tool “Significance analysis of microarrays
(SAM)” was used to identify the gene hit lists that were
differentially expressed in human muscle MG com-
pared with control muscle [20].Expression analysis
The gene hit lists established in parallel in humans and
rats were then submitted to two bioinformatic resources,
as previously described in the literature [13]. These two
resources provide different types of information:
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for interpreting microarray data or other interesting
gene sets using Gene Ontology hierarchies
(http://bioinfo.vanderbilt.edu/webgestalt/) [21].
Statistical analysis with relatively enriched gene
numbers can suggest biological areas that warrant
further study.
GOTM generates a GOTree, a tree-like structure
to navigate the gene ontology directed acyclic graph
for input gene sets. GOTM reports enrichments
that are statistically significant, as determined by a
hypergeometric test.
2. Ingenuity Pathways Analysis identifies pathways that
are overrepresented (https://analysis.ingenuity.com/pa
Ingenuity Mountain View, CA, USA) [22,23].Quantitative real-time PCR
Quantitative real-time PCR (Q-RT-PCR) on rat and
mouse samples was performed using a LightCycler
(Roche diagnostic) apparatus, as previously described in
the literature [15]. Each sample was run in duplicate and
the mean values were used for calculations. The expres-
sion levels of β-actin and GAPDH were monitored in
all rat samples and were found to be similar. The
primers were as follows: rat IL-6 forward: 5′-ctagtgcgt-
tatgcctaag-3′, IL-6 reverse: 5′-ccatctggctaggtaaca-3′; rat
IL-6R forward: 5′-ctgaatagagatgcccgt-3′, IL-6R reverse:
5′-gtcactcgcgtaaacc-3′; rat GAPDH forward: 5′-ccaaggag-
taagaaaccc-3′. GAPDH reverse: 5′-ggtgcagcgaactttat-3′;
rat β-actin forward: 5′-tactgccctggctcctagca-3′; β-actin re-
verse: 5′-tggacagtgaggccaggatag-3; mouse IL-6 forward:
5′-agttgccttcttgggactga-3′; IL-6 reverse: 5′-tccacgatttccca-
gagaac-3′; mouse IL-6R forward: 5′-agggtgtctgcttcctgcta-3′;
IL-6R reverse: 5′-catctgaggccactcagtca-3′; mouse Rpl32
forward: 5′-caccagtcagaccgatatgtgaaaa-3′; Rpl32 reverse:
5′-tgttgtcaatgcctctgggttt-3′.Cell culture
For the cellular experiments, we used immortalized cul-
tures of human myoblasts. These cells, called LHCNM2,
were previously derived from the pectoralis major
muscle of a 41-year-old male Caucasian heart-transplant
donor and immortalized by introduction of human tel-
omerase and cyclin-dependent protein kinase 4 [24].
The cells were cultured in medium containing four parts
Dulbecco’s modified Eagle’s medium (DMEM; 4.5 mg/ml
glucose) and one part medium 199, supplemented with
20% fetal bovine serum. For the differentiation studies,
the cells were trypsinized, counted, and 50,000 cells were
plated on to a 48-well plate. After 6–7 days, when the
cells had become confluent, the proliferation medium
was removed and replaced with DMEM (Gibco) supple-
mented with 10 mg/ml bovine insulin (Sigma-Aldrich,Saint-Quentin Fallavier France) and 100 mg/ml of human
apo-transferrin (Sigma-Aldrich), as previously described
in the literature [24].
Cell stimulation
The LHCNM2 cells were plated in 48-well plates
(50,000 cells/well). After 24 h, the medium was replaced
with a medium containing the MG patient sera (diluted
1/100 in the regular medium) or monoclonal antibodies
directed against AChR. Four different antibodies were
used: mAb 198 (IgG2a isotype), mAb 35 (IgG1 isotype),
mAb 155 (IgG2a isotype) [25], and anti-AChR (IgG1 iso-
type) from Acris Antibodies GmbH (reference SM1445).
The rat IgG2a and IgG1 isotype controls (clones 54447
and 43414) were purchased from R&D Systems, Inc.
(Minneapolis, MN). The results were normalized to the
control sera or the relevant isotype control, respectively.
The monoclonal antibodies and their isotype controls
were used at a concentration of 3 μg/ml.
Cell proliferation
Cell proliferation was assessed by flow cytometry using
Carboxyfluorescein Diacetate Succinimidyl Ester (CFSE)
dye, as previously described in the literature [26]. Briefly,
LHCNM2 cells were treated with CFSE (5 μM/1 × 106
cells) (Molecular Probes, Interchim, France) for 10 min
at 37°C. After washings, the cells were seeded in 24-well
plates, allowed to attach for 24 h, and then incubated
with monoclonal Abs. The cells were then collected after
24, 48, and 72 h incubation and acquired on a FACScali-
bur (BD Biosciences, Le Pont de Claix, France). The
cytometry analysis was completed using Flowjo software
Tree Star, Inc. (Ashland, OR, USA).
ELISA assays
Enzyme-linked immunosorbant assay (ELISA) was per-
formed on culture supernatants, as well as on muscle ex-
tracts to measure their IL-6 content. The frozen muscle
biopsies from patients were thawed and homogenized in
extraction buffer (Tris–HCl pH8 20 mM, NaCl 137 mM,
glycerol 10%, NP-40 1%, EDTA 2 mM) supplemented with
proteinase inhibitor cocktail (Complete, Roche, France).
The homogenates were then centrifuged and the super-
natant was kept at −80°C until analysis.
All of the reagents for the ELISA were from Immuno-
tools (Friesoythe, Germany) and used according to the
manufacturer’s instructions. Briefly, the plates were coated
overnight with the anti-IL-6 antibody at 4°C and washed 5
times. The aspecific sites were blocked for 1 h at 37°C. The
plates were washed 5 times and then samples were added,
incubated for 1 h at 37°C, and washed 5 more times. The
biotinylated IL-6 antibody was added, incubated 1 h at
37°C, and washed 5 times. Streptavidin-HRP was incubated
20 min at room temperature, and washed 5 times. TMB
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the stop solution. Optical density (OD) was read at
450 nm in an MRX Revelation ELISA plate reader (Dynex
Technologies, Inc. Chantilly, VA, USA). A standard curve
was obtained with serial dilutions of IL-6 and the results
were expressed in pg/ml. The cytokine concentration was
calculating using the mean of the duplicate measurements
for each sample.Analysis of Akt phosphorylation
Akt phosphorylation was assessed by a Western Blot.
The LHCN myotubes and myoblasts were treated for
two days with AChR antibodies or control isotype. On
the day of the analysis (differentiation day 7 (D7) for the
myotubes), they were rinsed and incubated in serum-
free medium for 3 h, before being treated with insulin
for 10 min. The LHCN cells were rinsed with phosphate
buffered saline and the proteins were then extracted
with an extraction buffer (Tris HCl pH8 20 mM, NaCl
137 mM, glycerol 10%, NP-40 10%, EDTA 2 mM) sup-
plemented with antiprotease and antiphosphatase mixes
(Complete Mini and PhosSTOP, respectively, Roche,
France). Cellular debris was eliminated by centrifugation
at 14,000 rpm for 20 min at 4°C. The protein extracts
were kept at −80°C prior to analysis.
The proteins were thawed on ice, denatured in Laemmli
buffer at 95°C for 5 min, separated by polyacrylamide gel
electrophoresis (Precise Tris-Hepes gels, Pierce, France), and
transferred to a nitrocellulose membrane. The protein trans-
fer was evaluated using Ponceau staining. The membrane
was saturated with 5% of milk proteins in Tris buffered sa-
line with 0.05% Tween (TBST), incubated with anti-pAkt
(Ser 473) rabbit antibody (dilution 1/500 to 1/1000) (Cell
Signaling Technology, Inc., Danvers, MA, USA) overnight
at 4°C, washed three times in TBST, incubated for one hour
in secondary antibody (anti-rabbit HRP, 1/10000, in 1% of
milk in TBST), washed three times in TBST, and revealed
with electrochemiluminescence (ECL) Prime on autoradiog-
raphy films (Amersham, GE Healthcare Bio-Sciences AB,
Uppsala, Sweden). The process of immunodetection was re-
peated with an anti-Akt antibody (Cell Signaling Technol-
ogy) to assess total Akt. Band intensities were evaluated
using Fiji Is Just ImageJ.Statistical analysis
For each data set, the normality of the samples was
tested using three normality tests (Kolmogorov-Smirnov,
D’Agostino and Pearson omnibus, and Shapiro-Wilk). If
the samples were characterized by a Gaussian distribu-
tion, the significance of the results was analyzed using a
Student’s t-test or ANOVA (more than 2 groups). Other-
wise, nonparametric tests were used: Mann–Whitney
for comparison of 2 groups and Kruskal-Wallis non-parametric ANOVA for comparison of 3 groups or
more. All analyses were done using GraphPad software
(GraphPad, San Diego, CA, USA).
Results
Categories of deregulated genes are similar in human MG
and rat EAMG muscle arrays
Transcriptome analysis was performed on both data sets,
human and rats. The data were analyzed using the
GOTM [21] that generates a tree-like structure and
yields two types of data: 1) the subcategories presenting
statistical changes and 2) the hierarchy between these
different subcategories. In this representation, the down-
stream category is a subgroup of the upstream category.
Figure 1 shows a strikingly similar tree for human and
rat myasthenic muscle compared with their respective
controls and suggests the involvement of genes included
in the muscle fiber category in the pathology of MG
(deregulated gene categories are marked in red).
Common signaling pathways are deregulated in MG and
EAMG muscles
We used the Ingenuity Pathway analysis software to com-
pare deregulated signaling pathways in the human and rat
muscle samples in order to identify cellular pathways that
are potentially involved in mechanisms underlying the
pathogenesis of MG. In Table 1, we list the major com-
mon canonical pathways that are significantly different in
both human and rat myasthenic muscles from their re-
spective controls. Interestingly, the IL-6 and IGF1 path-
ways already known to play a role in muscle metabolism
and function [27,28] were significantly represented in the
hit lists obtained from microarray analysis of muscle sam-
ples from both MG patients and EAMG. The deregu-
lated genes in the IL-6 and IGF1 pathways are listed in
Additional file 1: Table S1.
Since IL-6 has already been shown to be associated
with pathogenic mechanisms of MG [29], we decided to
focus on the IL-6 pathway involvement and the common
downstream actor of IL-6 and IGF1 pathways Akt/PKB.
IL-6 and IL-6R are altered in the muscles of animal
models
By using RT-PCR, we showed that the expression of IL-6
and IL-6R were altered in the muscles of EAMG rats and
mice in comparison with control CFA-immunized animals.
The expression of IL-6 was 3-fold lower in EAMG rats than
in control CFA rats (Figure 2A), but about 2-fold higher in
EAMG mice (Figure 2C); the expression of IL-6R was about
1.5–3-fold higher in muscles of EAMG animals than in
control-CFA rats or mice (Figures 2B and D). The contra-
dictory IL-6 results between mice and rats may be the result
of the disease severity. Indeed, the rat model is more effect-
ive and all rats exhibited a severe clinical score, whereas
Figure 1 Analysis of gene categories modified in human and rat myasthenia show similar results. Scheme of the significantly enriched
Gene Ontology categories in the cellular component system. Categories with significantly enriched gene numbers determined by a hypergeometric
test (http://bioinfo.vanderbilt.edu/webgestalt/) are indicated in red; categories shown in black are non-enriched. GOTM analysis demonstrated a strikingly
similar tree in human and rat muscle and demonstrates the involvement of genes included in the muscle fiber category (grey boxes).
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decrease. Only three mice had a severe phenotype and their
IL-6 transcript levels were very low (Figure 2C).
These results suggest that the autoimmune attack on
the muscle in the EAMG animal model may trigger the
changes in the expression of IL-6 and its receptor.
IL-6 production is increased in MG muscle and in muscle
cells treated with MG sera
To test whether IL-6 was also modified in human patients,
we first analysed the mRNA IL-6 level in MG muscle biop-
sies. We observed a trend for high IL-6 transcript levels in
MG samples compared to controls, but the difference was
not significant (data not shown). We then quantified the
IL-6 protein in extracts from eight MG muscle biopsies
and seven healthy biopsies. The IL-6 protein concentra-
tion was significantly higher in muscle extracts from





IGF-1 signaling 6.89*10−4 2.53*10−2
IL-6 Signaling 1.47*10−2 1.12*10−2
Nitric oxide signaling in the
cardiovascular system
3.39*10−2 3.47*10−2
Gene expression data for human and rat muscle were evaluated using Ingenuity
Pathway Analysis. The analysis used knowledge databases to identify global
canonical pathways associated with gene expression. The significance value of a
given canonical pathway, a measurement of the likelihood that the pathway
is associated with the data set by random chance, was calculated using a
right-tailed Fisher’s Exact Test, and values of p < 0.05 were assumed to be
statistically significant.investigate whether this increased IL-6 production was due
to pathogenic effects by MG sera, we tested the effects of
sera from MG patients (six SPMG, six SNMG patients, and
six age-matched controls) on IL-6 production by human
muscle cells. We found that sera from most MG patients (5
out of 6 SPMG and 6 out of 6 SNMG) induced a significant
increase in IL-6 production (p < 0.005 for the entire group
of MG patients) when normalized to the production by
cells treated with sera from age-matched controls. Interest-
ingly, the effect was stronger in the presence of sera from
SNMG patients than from SPMG patients. Sera from pa-
tients with other muscle diseases had no effect (Figure 3B).
The high level of IL-6 in the culture supernatants of cells
stimulated with MG sera was due to true production of IL-
6 by muscle cells in culture and not to the basal level of IL-
6 in the MG sera. Indeed, the IL-6 concentration in the sera
ranged from 5–15 pg/ml, and the sera was diluted 100
times. As a result, the contribution of the seric IL-6 in the
supernatant was lower than 0.3%.
IL-6 increase in muscle cells is caused by anti-AChR
antibodies
To investigate whether these effects on IL-6 production
were due to anti-AChR antibodies, we tested the effect
of several anti-AChR monoclonal antibodies (Figure 4).
For each antibody, the relevant isotype control was used
for normalization (IgG2a or IgG1). MAb 198 and mAb
35 are directed against the main immunogenic region on
the extracellular part of the alpha subunit and are
known to cause not only antigenic modulation but also







































Figure 2 IL-6 and IL-6R expression is modified in muscle from animal models of MG. mRNA expression of IL-6 and IL-6R in muscles of
EAMG and control CFA-immunized rats (A and B) and mice (C and D). mRNA expression levels of IL-6 (A and C) and IL-6R (B and D) were
determined by Q-RT-PCR. In IL-6 transcript levels for mice, the EAMG group was separated in EAMG score with a zero-to-moderate clinical score
(<6) and EAMG with a high score (>7). The clinical weakness was evaluated by weight loss, reduced grip strength, and reduced ability to hang on
an inverted grid. β-Actin for rats and Rpl32 for mice were used as an inner control for normalization of IL-6 and IL-6R. The groups were compared using
t-tests for significance. ANOVA was used for mice IL-6 transcripts levels (C, p = 0.0315). Post-test comparisons of groups were not individually significant,
but a trend could be observed (Controls versus EAMG (0–6) p = 0.0516; EAMG (0–6) versus EAMG (7–9) p = 0.0792) ***p < 0.001; **p < 0.01; *p < 0.05.
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side of the α-subunit [25]. The Acris mAb, a commercial
monoclonal antibody, reacts with an unknown epitope
of the human AChR. We observed that mAb 198 had a
larger effect on IL-6 production by myotubes than mAb
35, mAb 155 or Acris mAb (Figure 4A). These data sug-
gest that the induction of IL-6 by anti-AChR mAbs is
dependent on the epitope recognized by the antibody.
We compared the effect of antibodies on undifferentiated
myoblasts and myotubes. Interestingly, the IL-6 increase in-
duced by anti-AChR antibodies was higher in myotubes than
in myoblasts for all of the antibodies. For mAb 155 and Acris,
the IL-6 levels were unchanged in myoblasts (Figure 4B). This
finding could be related to the higher expression of AChR in
differentiated myotubes, which is illustrated here with the
mRNA level of the α- and β- subunits (Figure 4C).
In MG, anti-AChR antibodies are produced continu-
ously. Therefore, in order to better mimic the patho-
logical situation, we added anti-AChR mAb 198 at
several time points during cell culture and analyzed the
IL-6 production. Figure 4D shows that the system is not
saturated, since the addition of anti-AChR antibodies at
three successive time points (Figure 4D, bar D) resultedin a higher production of IL-6 compared with additions
at a single time point (Figure 4D, bar A) or two time
points (Figure 4D, bars B and C).
Antibody effects on IL-6 production are due to a
transcriptional mechanism
To determine whether the increased IL-6 production was
due to an increased cell number induced by anti-AChR
antibodies, we compared the proliferation of human
muscle cells in the presence of anti-AChR antibodies or
isotype controls using CFSE labeling. There was no differ-
ence in the CFSE fluorescence intensity whether the cells
were cultured in the presence of anti-AChR or isotype-
matched antibodies (Figure 5A). These results suggest that
the anti-AChR antibodies do not induce muscle cell pro-
liferation, emphasizing that the increased production of
IL-6 was not due to an increased number of cells.
To analyze whether the antibody effects on IL-6 produc-
tion were due to a transcriptional mechanism, we performed
a kinetic study on protein and RNA levels in the muscle cells
in the presence of mAb 198. The results were normalized to
the IgG2a isotype control. As shown in Figure 5B, the










































Figure 3 IL-6 protein is increased in muscle from MG patients
and is induced by MG sera in muscle cells. The IL-6 levels were
determined by ELISA in protein extracts of human muscle biopsies
(A) or in the medium of myoblasts cultured for 24 h with sera from
SPMG or SNMG patients, or other skeletal muscle diseases or healthy
controls diluted 1/100 in the culture medium (B). Each serum was
tested twice. The significance was evaluated using t-tests between
groups. **p < 0.01; *p < 0.05.
Maurer et al. Acta Neuropathologica Communications  (2015) 3:1 Page 8 of 14with higher variations for the mRNA (up to 400% and 150%
for mRNA and protein levels, respectively). Interestingly,
2 hours after the addition of antibodies, we observed an
early peak of protein expression associated with a marked
reduction in the IL-6 mRNA level, suggesting that, at the
early phase, IL-6 is translated from a pre-existing pool of
IL-6 mRNA, as previously described for AChR expression [8].
Altogether, these results indicate that the effects of anti-
AChR antibody on IL-6 production cannot be attributed
to a higher proliferation of myoblasts, but rather to an in-
creased transcription rate or a post-transcriptional mech-
anism such as increased transcript or protein stability. It is
noteworthy that the increased level of transcripts was
acute and transient while the high IL-6 protein expression
was moderate and quite stable.Phosphorylation of Akt, a downstream effector of IGF-1
and IL-6, is impaired by AChR monoclonal antibodies
In order to understand how muscle cells are affected, we
investigated a downstream effector of IGF-1 and IL-6,
PKB/Akt. The Akt pathway plays several roles in muscle
physiology. For instance, it promotes growth through
protein synthesis and mediates glucose capture through
translocation of glucose transporter (GLUT4) at the
sarcolemma. It is activated by IGF-1, insulin, and other
growth factors. IL-6 is known to have a potentializing
effect on an acute, short-term exposure such as an
exercise-induced production of IL-6 by muscle cells [30]
and an inhibiting effect on a chronic, long-term expos-
ure such as an inflammatory state [31,32].
We investigated the pAkt/total Akt ratio in response to
insulin in human muscle cells exposed to AChR monoclo-
nal antibodies over the course of 48 h, which corresponds
to a long-term exposure in order to mimic the pathological
myasthenic situation. In myoblasts, the antibodies did not
change significantly the pAkt/Akt ratio (Figure 6B), but did
so in myotubes (Figure 6C). As expected, Akt phos-
phorylation was reduced in the presence of anti-AChR
antibodies.
These results clearly validate the involvement of the
IGF-1/Akt pathway identified in the microarray and
open a new field of investigation in the pathogenesis of
myasthenia in muscles.
Discussion
The aim of this study was to investigate the molecular
mechanisms occurring in the muscle of MG patients
and EAMG models. Our major findings are as follows:
1) The muscle signatures associated with the disease
were strikingly similar in MG patients and in induced
EAMG in rats, and revealed the involvement of IL-6 and
IGF-1 pathways; 2) IL-6 had an altered expression in the
muscles of EAMG models and MG muscle compared to
controls, and was induced in cultured muscle cells
treated with anti-AChR antibodies; 3) Akt, a down-
stream effector of IGF-1 pathway on which IL-6 is
known to have a negative effect, exhibited defective
phosphorylation in cultured muscle cells treated with
anti-AChR antibodies.
Role of IL-6 in pathogenic mechanisms in MG muscle
In this study, we have identified disease-associated gene
signatures and pathways with a microarray approach. It
is worth noting that the IL-6 and IGF-1 pathways were
found to be significantly deregulated in both the spon-
taneous human disease and the model induced in rats.
IL-6 was originally discovered within the immune sys-
tem. Numerous studies, however, have revealed that IL-6
is produced by, and released from, contracting skeletal

















































































































Figure 4 Monoclonal anti-AChR antibodies increase IL-6 production by muscle cells. The LHCNM2 cells were cultured as described in the
Materials and Methods section, as myoblasts or after differentiation into myotubes. (A) IL-6 production was measured by ELISA and normalized to
controls (without antibody). Myotubes were treated with anti-AChR antibodies (198, 155, 35 and Acrys), their isotype controls (IgG2a, IgG1), or left
untreated (Ctl). The data come from four experiments, each including 4–6 replicates. (B) For some antibodies, the effect on myotubes (black bars)
and myoblasts (white bars) was compared. The data come from three experiments, each including 2–4 replicates. (C) The expression of AChR
subunits in myotubes (black bars) and myoblasts (white bars) was assessed by Q-RT-PCR (n = 4). (D) Addition of the anti-AChR mAb 198 was
performed at several time points and all supernatants were analyzed at 72 h. mAb 198 was added once (bar A), twice (bars B and C), or at three
consecutive time points (bar D). The results shown are from two wells for each condition in a representative experiment. Bars and error bars
represent mean ± SEM. ***p < 0.001; **p < 0.01; *p < 0.05.
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absence of muscle damage. Tsujinaka et al. [34] have dem-
onstrated that overexpression of IL-6 in transgenic mice
causes muscle atrophy and increases levels of cathepsins
in muscles, indicating that IL-6 is involved in regulating
muscle protein breakdown, which can be prevented by the
administration of anti-IL-6R antibodies [35]. Muscle atro-
phy is sometimes observed in MG patients, especially in
type II fibers [36,37], but whether atrophy is due to the in-
creased IL-6 production by the autoantibodies remains an
open question. This possibility is in agreement with a
study by Tuzun et al., who demonstrated a direct role for
IL-6 in muscle cell destruction [38] and that of Aricha
et al., who showed a significant improved clinical state of
MG-induced rats after anti-IL-6 treatment [39].
Our ex vivo experiments show a decreased level of
#IL-6 mRNA in the muscle of EAMG rats, whereas the
IL-6 mRNA level was increased in the muscle of EAMGmice. This apparent contradiction may be linked to the se-
verity of the disease: muscles from rats were harvested
when they reached an elevated score, whereas mice did
not systematically show clinical signs. Moreover, the most
affected mice had the lowest IL-6 mRNA levels, which
suggests a correlation between the level of IL-6 and the
degree of muscle damage. Thus, except in cases of very se-
vere disease, IL-6 production appears to be activated
in vitro (muscle cells stimulated with anti-AChR anti-
bodies) and ex vivo (IL-6 protein in human MG muscle
and IL-6 mRNA in mouse muscle). Interestingly in MG
patients, the increase of IL-6 mRNA was not significant
(data not shown), while the level of IL-6 protein was sta-
tistically increased. This could be explained by the higher
stability of the protein IL-6 compared to the mRNA that
is quite unstable [40]. The functional involvement of IL-6
was further demonstrated in the cultures of muscle cells
treated by MG sera or anti-AChR monoclonal antibodies









































































Figure 5 Mechanisms of action of mAb 198. (A) Comparison of the proliferation of human muscle cells in the presence of anti-AChR antibodies
or isotype control using CFSE. Fluorescence geometric means (GM) decreased with time but did not exhibit any differences when the cells were
treated with anti-AChR mAb or isotype control (3 μ/ml). (B) Kinetics of IL-6 production by LHCNM2 after stimulation with mAb 198 anti-AChR antibody
is represented in black, and mRNA expression is represented in grey. IL-6 production was measured by ELISA assays and normalized to isotype
controls (n = 4 for each group and time). mRNA expression was measured by Q-RT-PCR and was normalized to GAPDH (n = 2 for each group
and time). Mean ± SEM is represented.
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protein production.
Together, these data show that IL-6 is highly deregu-
lated in the muscle of MG patients and EAMG models.
The natural course of the disease may then have two
stages, with different levels of IL-6 transcripts produced
by the muscle: increased IL-6 production during mild
stages, and decrease in severe stages. In order to better
understand this process, it would be informative to inves-
tigate the muscle characteristics in those stages; myoatro-
phy, for example, may explain this change in the response.
Although IL-6 high levels are known to promote muscle
atrophy, whether IL-6 production is reduced in the atro-
phic fibers has not been described.Why and how is IL-6 regulated in MG muscle?
The mechanisms underlying the increased production of
IL-6 by the muscle cells after the attack by the anti-
AChR antibodies are not clear. IL-6 is regulated by cyto-
kines. TNF-alpha and IL-1beta induce IL-6 production
by cultured skeletal muscle cells via the activation of a
MAPK signaling pathway [41,42]; IL-10 has an inhibitory
effect on IL-6 mRNA and protein expression. IL-6 pro-
duction is also controlled by an autocrine regulation
exerted by IL-6 [43]. Therefore, the increase in IL-6 in-
duced by the antibodies could be mediated by increased
TNF-alpha production. We tested this assumption by
measuring TNF-alpha in the muscle after treatment with
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Figure 6 Akt phosphorylation is decreased by AChR antibodies in myotubes but not in myoblasts. Immortalized human muscle cells
(LHCN) were differentiated over 7 days (D7) or kept as myoblasts (D0). AChR monoclonal antibodies (mAb 198 or mAb 155) or isotype control
(IgG2a) were added 48 h before the analysis. The cells were stimulated with insulin or not (Unstimulated) and the proteins were extracted and
analyzed via a Western Blot. A representative image of the Western Blot result is shown in panel A. The ratio between pAkt and total Akt
band intensities is represented in graphs for myoblasts (B) and myotubes at D7 (C). In each group, the sample size was n = 5–7 from three
independent experiments. Asterisks represent significance given by an ANOVA analysis versus the control condition (Dunnett’s post test).
Mean ± SEM is represented. ***p < 0.001; **p < 0.01; *p < 0.05.
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IL-6 can potentially be modulated by many different
cytokines and further investigations are needed to deter-
mine the mechanism responsible for this increase.
It is worth noting that SPMG sera had a weaker effect
on IL-6 production than the SNMG sera, which does
not support the hypothesis that the IL-6 increase was
dependent on anti-AChR antibodies, although the subse-
quent experiments using monoclonal anti-AChR anti-
bodies demonstrated that they were sufficient to induce
IL-6 production by the muscle cells. This finding could
be explained by the immediate effect of SPMG sera on
the internalization of AChR, limiting this functionalmechanism. In addition, anti-AChR antibodies in SPMG
sera are degraded with their targets during the internal-
ization process. It is therefore possible that anti-AChR
antibodies become limiting in the in vitro assay, whereas
they are produced continuously in vivo. In SNMG, the
internalization induced by the sera is very limited [44],
favoring this newly described mechanism. In accordance
with this hypothesis, Leite et al. [45] show that some
SNMG patients possess anti-AChR antibodies detectable
only on whole clustered AChR. One can speculate that
these anti-AChR antibodies against clustered-AChR do
not reduce AChR numbers, but lead to a functional sig-
naling effect. All SNMG were negative for anti-MuSK
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LRP4 antibodies that may have a similar effect. We can
also suppose that other factors present in the SNMG
sera are able to induce a similar response to the AChR
antibodies. The precise mechanisms are still elusive but
they appear specific to myasthenia since no control iso-
type antibodies or other muscle disease sera elicit this
response from muscle cells.
Consequences of the overproduction of IL-6 in MG
muscle: a new mechanism of action of the anti-AChR
antibodies?
Three mechanisms of action of anti-AChR antibodies have
been described thus far: accelerated internalization of
AChR, complement-dependent degradation of the recep-
tor, and blocking of acetylcholine binding to AChR [46].
Our results provide arguments in favor of an additional
mechanism of action that could be defined as a functional
mechanism.
The increase in IL-6 production by muscle cells ex-
posed to anti-AChR antibodies could have significant
consequences on muscle biology, but also on immune
responses. Indeed, myoblast proliferation is stimulated
by IL-6, and satellite cell proliferation is regulated by an
autocrine IL-6 effect [47,48]. Further evidence provided
by genetic studies showed that IL-6-deficient mice are
resistant to the development of autoimmune diseases
such as myocarditis and EAMG [49,29]. This finding was
associated with a significant reduction in germinal center
formation, reduction in anti-AChR antibody production,
and impaired upregulation of complement C3. Because
anti-AChR antibodies and C3 activation contribute to the
autoimmune destruction of AChR, therapeutic downregu-
lation of IL-6 could control the deleterious events occur-
ring at the neuromuscular junction in EAMG and likely
in the early stages of MG [29]. Interestingly, the IL-1
receptor-mediated therapeutic effect in the murine EAMG
model is associated with downregulation of TNF-alpha,
IL-6, and C3 [50]. In addition, we very recently showed
that anti-IL-6 therapy improves the clinical state of MG
[39]. The increased IL-6 production induced by some
antibodies could in turn lead, in addition to its pro-
inflammatory role, to several functional consequences
affecting the metabolism of the muscle, its differenti-
ation, and its regeneration.
Is there a link between IL-6 overproduction and the
IGF-1/Akt pathway in MG?
We have shown that monoclonal anti-AChR antibodies re-
duce Akt phosphorylation in response to insulin. Interest-
ingly, mAb 155 displayed a dose-dependent response and
mAb 198 did not; the latter had a stronger effect on IL-6
production. Several explanations could be proposed: 1)
There is a threshold effect of IL-6 on Akt phosphorylationthat was exceeded in both mAb 198 dilutions, but only in
one of the mAb 155 dilution; 2) the effect is not dependent
on IL-6; 3) we cannot exclude that a low level of IL-6 (in
the case of Mab155) is due to its overconsumption by the
cells.
Although it has been described that IL-6 has an inhi-
biting effect on Akt pathway in chronic exposure [31], it
remains to be determined if the action of anti-AChR
antibodies is mediated by IL-6. Unveiling impaired Akt
phosphorylation caused in muscle cells by AChR anti-
bodies is a first step to defining those consequences. It
remains to be determined how this mechanism is trans-
lated in terms of muscle physiology, since Akt is in-
volved in many processes such as growth, glucose
metabolism, and so on. It is interesting that differenti-
ated and undifferentiated muscle cells do not respond in
the same way to anti-AChR antibodies, indicating that
each cell type may play a distinct role in pathogenesis.
Although not frequent, atrophy may be observed in MG
and could be a direct consequence of muscle growth im-
pairment by Akt pathways [36]. Metabolic aspects should
also be investigated since they may play a role in muscle
weakness and fatigue, in which case a complementary
therapy activating this metabolic pathway could alleviate
myasthenia symptoms.
Conclusions
Our results describe a new mechanism of action of the
anti-AChR antibodies in the muscle of MG patients and
EAMG models, including IL-6 and IGF-1/Akt pathways.
This mechanism could be defined as a functional mech-
anism. The reduced phosphorylation of Akt by the anti-
AChR antibodies may have a significant impact on the
muscle fatigability observed in MG patients. The in-
creased production of IL-6 by MG muscle may have an
effect on the muscle function, and on systemic inflam-
mation. Modulating their protein products could repre-
sent a new therapeutic strategy for MG.
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Additional file 1: Table S1. Deregulated genes for the IGF-I and
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the IL-6 pathway, 13 genes were deregulated in patients and 13 in rats.
Highlighted genes are common between the two pathways.
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